Scotiabank Sticks to Bullish Amgen Forecast Amid Strong Growth Prospects

Scotiabank has reaffirmed its Sector Outperform rating on Amgen's stock, setting a price target of $500.00. This prediction implies an upside of 19.6% from the September 28 close of $418.13.

The bank cites Amgen's diverse and robust product portfolio as one of the key drivers for its optimistic outlook. The company's strong offerings in oncology and rare diseases, bolstered by strategic acquisitions such as Horizon and Onyx Pharmaceuticals, have enhanced its market potential.

Scotiabank also highlights Amgen's commitment to innovation and development, reflected in high-single-digit year-over-year growth in non-GAAP R&D expenditures. This financial outlook supports the firm's growth trajectory and justifies the Sector Outperform rating.